Startseite Kongressberichte & Archiv ESMO World Congress on Gastrointestinal Cancer Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 2

Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 2

SO-007: Regorafenib plus nivolumab in patients with advanced colorectal (CRC) or gastric cancer (GC): an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)
Hiroki Hara, et al.

The conclusion from authors abstract:

The combination of regorafenib 80mg plus nivolumab had a manageable safety profile and encouraging anti-tumor activity in MSS GC and CRC pts, which warrants further investigations in a larger cohort. Updated biomarker analysis will be presented.



LBA-004: Phase 2 study results of murlentamab, a monoclonal antibody targeting the Anti-Mullerian-Hormone-Receptor II (AMHRII), acting through Tumor Associated Macrophage engagement in advanced/metastatic colorectal cancers
Eric Van Cutsem, et al.

The conclusion from authors abstract:

This pilot study suggests longer than expected PFS for murlentamab and FTD/TPI in advanced mCRC, especially in patients with high AMHRII expression. Immune activation of the macrophage / cytotoxic T cell cascade was observed in tumor microenvironment as well as in peripheral blood. These results together with murlentamab’s innovative immunological mode of action support its further development in combination with standard chemotherapies and/or immunological agents in colorectal cancers.



SO-008: Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: Safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study
Philippe Cassier, et al.

The conclusion from authors abstract:

Ramucirumab plus merestinib is tolerable and may have antitumor activity in biomarker-unselected, heavily pretreated patients with mCRC. Pharmacokinetic data for ramucirumab and merestinib were consistent with corresponding monotherapy data, indicating that drug-drug interactions between ramucirumab and merestinib are unlikely. Our long-term PFS and OS data are provocative; efforts to identify biomarker signals associated with this sustained clinical activity are underway.



SO-009: Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer
Eric Van Cutsem, et al.

The conclusion from authors abstract:

Safety, clinical and translational research data comparing autologous and allogeneic approaches at the end of the dose-escalations will be presented, including any potential difference in terms of cell engraftment. These studies will provide critical information to support the development of CAR-T therapy in solid tumors.

 

SO-010: Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of the anti-EGFR Tomuzotuximab (TO) in combination with the anti-MUC1 Gatipotuzumab (GAT) in patients with EGFR positive solid tumors
Elena Garralda, et al.

The conclusion from authors abstract:

Preliminary results of this study warrant further investigation of the combination of TO and GAT in refractory pat with K-RAS WT CRC.